Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Takeda Pharma (TKPYY)

Takeda Pharma (TKPYY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 25,919,552
  • Shares Outstanding, K 1,562,360
  • Annual Sales, $ 15,935 M
  • Annual Income, $ 1,682 M
  • 60-Month Beta 0.42
  • Price/Sales 1.64
  • Price/Cash Flow N/A
  • Price/Book 1.36
  • Price/Earnings ttm 12.22
  • Earnings Per Share ttm 1.37
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 02/07/19
  • Annual Dividend & Yield 0.58 (3.48%)
  • Most Recent Dividend 0.288 on 09/27/18
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
15.5000 +7.03%
on 12/18/18
19.2300 -13.73%
on 11/26/18
-2.6300 (-13.68%)
since 11/21/18
3-Month
15.5000 +7.03%
on 12/18/18
21.9399 -24.38%
on 09/26/18
-4.3650 (-20.83%)
since 09/21/18
52-Week
15.5000 +7.03%
on 12/18/18
31.2900 -46.98%
on 02/01/18
-11.8100 (-41.58%)
since 12/21/17

Most Recent Stories

More News
Takeda Provides Update on TOURMALINE-AL1 Phase 3 Trial in AL Amyloidosis

Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE: TAK) today announced that the Phase 3 TOURMALINE-AL1 clinical trial in patients with relapsed or refractory systemic light-chain...

TKPYY : 16.5900 (-0.90%)
Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Takeda Pharmaceutical Company Ltd. (TAK)

Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Takeda Pharmaceutical Company Ltd. ("Takeda" or the "Company") (NYSE: TAK). Such...

TKPYY : 16.5900 (-0.90%)
TAK : 17.36 (-0.52%)
Takeda Presents Results from Lung Portfolio Including Phase 1/2 Study of TAK-788 in a Rare Form of NSCLC and New Data on Overall Health-Related Quality of Life for ALUNBRIG(R) (brigatinib)

--- Takeda's Growing Lung Portfolio is Driven by a Dedication to Developing Innovative Therapies for People Living with NSCLC -

TKPYY : 16.5900 (-0.90%)
Takeda Makes First Private Sector Pledge for Global Fund Replenishment

Takeda Pharmaceutical Company Limited ("Takeda") (TSE:4502/NYSE:TAK) today became the first private sector company to announce a financial commitment to the Global Fund's Sixth Replenishment....

TKPYY : 16.5900 (-0.90%)
Anaplastic Lymphoma Kinase (ALK) Inhibitors: Worldwide Market Analysis & Forecast 2019-2023 with F. Hoffmann-La Roche, Novartis, Pfizer, and Takeda Pharmaceutical Co Dominating - ResearchAndMarkets.com

The "Global Anaplastic Lymphoma Kinase (ALK) Inhibitors Market 2019-2023" report has been added to ResearchAndMarkets.com's offering.

TKPYY : 16.5900 (-0.90%)
Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Takeda Pharmaceutical Company Ltd. (TAK)

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Takeda Pharmaceutical Company Ltd. ("Takeda" or the "Company") (NYSE: TAK). Such investors are encouraged...

TKPYY : 16.5900 (-0.90%)
TAK : 17.36 (-0.52%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Takeda Pharmaceutical Company Limited - TAK

Pomerantz LLP is investigating claims on behalf of investors of Takeda Pharmaceutical Company Limited ("Takeda" or the "Company") (NYSE: TAK). Such investors are advised to contact Robert S. Willoughby...

TKPYY : 16.5900 (-0.90%)
TAK : 17.36 (-0.52%)
Takeda to Showcase Growing Pipeline and Diversified Portfolio of Oncology Products at Upcoming Scientific Congresses

--- Eight Takeda-Sponsored Abstracts Accepted for Presentation at ASCO 2019 and 11 Abstracts Accepted for Presentation at EHA 2019 -

TKPYY : 16.5900 (-0.90%)
Takeda to Highlight Compelling New Data and Portfolio Advances for Gastrointestinal (GI) Diseases at DDW 2019

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) ("Takeda") today announced that it will present more than 25 company-sponsored abstracts and share an overview of innovative pipeline research...

TKPYY : 16.5900 (-0.90%)
Takeda and Frazier Healthcare Partners Announce Collaboration to Launch Phathom Pharmaceuticals

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) ("Takeda") and Frazier Healthcare Partners ("Frazier") today announced a collaboration to launch Phathom Pharmaceuticals, a biopharmaceutical...

TKPYY : 16.5900 (-0.90%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

See More Share

Trade TKPYY with:

Key Turning Points

2nd Resistance Point 17.1900
1st Resistance Point 16.8900
Last Price 16.5900
1st Support Level 16.3200
2nd Support Level 16.0500

See More

52-Week High 31.2900
Fibonacci 61.8% 25.2582
Fibonacci 50% 23.3950
Fibonacci 38.2% 21.5318
Last Price 16.5900
52-Week Low 15.5000

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar